TREX1 has a protumorigenic effect by inhibiting the cGAS-STING-mediated immune activation within and outside the tumor and by limiting checkpoint activation of the adaptive immune response in the tumor microenvironment [2, 3, 7, 8, 29, 35, 36, 43–45]. The gene discussed is STING1; the disease is neoplasm.